Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Arecor Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6UI vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Arecor Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Arecor Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics (STU:6UI) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arecor Therapeutics and its competitors. Over the past decade, Arecor Therapeutics' Days Payable has ranged from 217.27 to 1,251.16. According to the industry distribution chart, Arecor Therapeutics ranks #103 out of 703 companies in the Biotechnology industry, placing it in the top 14.7%.
Is Arecor Therapeutics' Days Payable too high?
Arecor Therapeutics' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 217.27 to a high of 1,251.16. Based on the distribution chart, Arecor Therapeutics ranks #103 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arecor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arecor Therapeutics ranks #103 out of 703 companies for Days Payable. This places Arecor Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Historically, Arecor Therapeutics' own Days Payable has ranged from 217.27 to 1,251.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arecor Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arecor Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (STU:6UI) has a current Days Payable of 0.00. The stock's GF Value™ is €0.49, compared to a current price of €0.69 — trading 39.8% above its estimated fair value. The current Days Payable is 0.00. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Arecor Therapeutics (STU:6UI), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (STU:6UI) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of €0.69 is trading 39.8% above its estimated GF Value™ of €0.49.
Key valuation signals for STU:6UI:
Days Payable: 0.00
GF Value™: €0.49 vs. price of €0.69 (39.8% above fair value)
No single metric tells the full story. See the STU:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score
Get the complete analysis for STU:6UI
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6UI has been successfully added to your 
